

## Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

**BARCELONA, SPAIN and CAMBRIDGE, MA, July 5, 2016** – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has designated its next drug, ORY-3001, for preclinical development. This is the third drug candidate produced by the Company, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of, yet undisclosed, non-oncological conditions.

Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first drug currently in Phase IIA in acute leukemia that validates the platform scientifically and clinically. This Platform has so far produced two compounds in clinical development with multiple indication opportunities for both drugs

LSD1 is an enzyme that removes methyl marks from lysine 4 of histone H3, a nucleosomal protein involved in the organization and control of accessibility of DNA for transcription. Modifications of these histone marks are associated with changes in gene transcription. Modulation of LSD1 activity can be used to change the transcriptional balance in cells, and LSD1 has been suggested to be a potential target for certain cancer types, for neurodegenerative disorders, for treatment of viral infections, and other indications.

Oryzon's LSD1 drugs are pioneering the Histone demethylases field with its forerunner oncologic drug that was licensed to Roche in 2014 and a second program in Phase I in neurodegenerative disorders. The company will focus its therapeutic efforts with this third drug preferentially in non-oncological orphan indications.

ORY-3001 is an enantiomerically pure, potent and selective compound with good pharmacological properties, orally bioavailable, with optimal PK, safety and selectivity profile. After successful completion of regulatory toxicology studies, the company expects to move ORY-3001 into Clinical Phase I/IIa studies in the H2 of 2017.

### About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to

develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit [www.oryzon.com](http://www.oryzon.com).

#### **FORWARD-LOOKING STATEMENTS**

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.

Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public.

Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**US Contact:****The Trout Group****Maria Lomaka**

+1 646 378 2932

**[mlomaka@troutgroup.com](mailto:mlomaka@troutgroup.com)****Spain:****ATREVIA****Patricia Cobo**

+34 91 564 07 25

**[pcobo@atrevia.com](mailto:pcobo@atrevia.com)****The Company:****Anna K Baran****IR Director**

+44 (0) 752 1083 006

**[abaran@oryzon.com](mailto:abaran@oryzon.com)**